Overview

Phase I EGFR BATs in Newly Diagnosed Glioblastoma

Status:
Active, not recruiting

Trial end date:
2022-08-31

Target enrollment:

Participant gender:

Summary

This is a phase I trial using EGFR Bi-armed Activated T-cells (BATs) in combination with standard of care temozolomide (TMZ) and radiation (RT) in patients with glioblastoma (GBM). The purpose of the study is to determine a safe dose of EGFR BATs when given with standard of care therapy.

Phase:

Phase 1

Details

Lead Sponsor:

University of Virginia

Treatments:

Antibodies, Bispecific